Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 200 citing articles:

Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Thomas A. Zelniker, Eugene Braunwald
Journal of the American College of Cardiology (2020) Vol. 75, Iss. 4, pp. 422-434
Closed Access | Times Cited: 413
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
Ralph A. DeFronzo, William Reeves, Alaa S. Awad
Nature Reviews Nephrology (2021) Vol. 17, Iss. 5, pp. 319-334
Closed Access | Times Cited: 381
Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
Milton Packer, Javed Butler, Gerasimos Filippatos, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 10, pp. 1270-1278
Open Access | Times Cited: 249
SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action
Milton Packer
Diabetes Care (2020) Vol. 43, Iss. 3, pp. 508-511
Open Access | Times Cited: 197
Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control
Giulia Borghetti, Dirk von Lewinski, Deborah Eaton, et al.
Frontiers in Physiology (2018) Vol. 9
Open Access | Times Cited: 194
Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients
Laween Uthman, Antonius Baartscheer, Cees A. Schumacher, et al.
Frontiers in Physiology (2018) Vol. 9
Open Access | Times Cited: 169
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Mohamad Arow, Maayan Waldman, Dor Yadin, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 161
Cardiac transmembrane ion channels and action potentials: cellular physiology and arrhythmogenic behavior
András Varró, Jakub Tomek, Norbert Nagy, et al.
Physiological Reviews (2020) Vol. 101, Iss. 3, pp. 1083-1176
Open Access | Times Cited: 154
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3651-3651
Open Access | Times Cited: 142
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme
Faı̈ez Zannad, João Pedro Ferreira, Javed Butler, et al.
European Heart Journal (2022) Vol. 43, Iss. 48, pp. 4991-5002
Open Access | Times Cited: 134
Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis
Kai Jiang, Yue Xu, Dandan Wang, et al.
Protein & Cell (2021) Vol. 13, Iss. 5, pp. 336-359
Open Access | Times Cited: 124
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
Alberto Preda, Fabrizio Montecucco, Federico Carbone, et al.
Cardiovascular Research (2024) Vol. 120, Iss. 5, pp. 443-460
Open Access | Times Cited: 31
Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial
Milton Packer, Brian Claggett, Martin Lefkowitz, et al.
The Lancet Diabetes & Endocrinology (2018) Vol. 6, Iss. 7, pp. 547-554
Closed Access | Times Cited: 146
A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats
Ayşegül Durak, Yusuf Olğar, Sinan Değirmenci, et al.
Cardiovascular Diabetology (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 142
Obesity-Related Heart Failure With a Preserved Ejection Fraction
Milton Packer, Dalane W. Kitzman
JACC Heart Failure (2018) Vol. 6, Iss. 8, pp. 633-639
Open Access | Times Cited: 134
Characterization of the inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease
Milton Packer, Carolyn S.P. Lam, Lars H. Lund, et al.
European Journal of Heart Failure (2020) Vol. 22, Iss. 9, pp. 1551-1567
Open Access | Times Cited: 127
Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors
Christopher S. Wilcox
Hypertension (2020) Vol. 75, Iss. 4, pp. 894-901
Open Access | Times Cited: 122
The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments
Álvaro García‐Ropero, Juan J. Badimón, Carlos G. Santos‐Gallego
Expert Opinion on Drug Metabolism & Toxicology (2018) Vol. 14, Iss. 12, pp. 1287-1302
Closed Access | Times Cited: 116
Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium
Donato Cappetta, Antonella De Angelis, Loreta Pia Ciuffreda, et al.
Pharmacological Research (2020) Vol. 157, pp. 104781-104781
Closed Access | Times Cited: 106
A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium‐glucose co‐transporter‐2 inhibitors
Emily Brown, Surya Panicker Rajeev, Daniel J. Cuthbertson, et al.
Diabetes Obesity and Metabolism (2019) Vol. 21, Iss. S2, pp. 9-18
Closed Access | Times Cited: 95
Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial
Carolyn S.P. Lam, Chinthanie Ramasundarahettige, Kelley R. Branch, et al.
Circulation (2021) Vol. 145, Iss. 8, pp. 565-574
Open Access | Times Cited: 92
Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes
Milton Packer
Diabetes Care (2017) Vol. 41, Iss. 1, pp. 11-13
Open Access | Times Cited: 91
Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts
Laween Uthman, Rianne Nederlof, Otto Eerbeek, et al.
Cardiovascular Research (2019) Vol. 115, Iss. 10, pp. 1533-1545
Open Access | Times Cited: 89
Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition
Nitin A. Das, Andrea J. Carpenter, Anthony Belenchia, et al.
Cellular Signalling (2019) Vol. 68, pp. 109506-109506
Open Access | Times Cited: 87
Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium–glucose cotransporter 2 inhibitors
Milton Packer
European Journal of Heart Failure (2020) Vol. 22, Iss. 4, pp. 618-628
Open Access | Times Cited: 85
Page 1 - Next Page

Scroll to top